B‑Raf mutation and papillary thyroid carcinoma patients (Review)
- Authors:
- Lixin Jiang
- Haidi Chu
- Haitao Zheng
-
Affiliations: Department of General Surgery, Affiliated Hospital of Qingdao University, Yantai Yuhuangding Hospital, Yantai, Shandong 264000, P.R. China - Published online on: March 1, 2016 https://doi.org/10.3892/ol.2016.4298
- Pages: 2699-2705
-
Copyright: © Jiang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
This article is mentioned in:
Abstract
|
Pelizzo MR, Dobrinja C, Casal Ide E, Zane M, Lora O, Toniato A, Mian C, Barollo S, Izuzquiza M, Guerrini J, et al: The role of BRAF(V600E) mutation as poor prognostic factor for the outcome of patients with intrathyroid papillary thyroid carcinoma. Biomed Pharmacother. 68:413–417. 2014. View Article : Google Scholar : PubMed/NCBI | |
|
Davies L and Welch HG: Increasing incidence of thyroid cancer in the United States, 1973–2002. JAMA. 295:2164–2167. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, et al: Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 19:1167–1214. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW and Wiersinga W: European Thyroid Cancer Taskforce: European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 154:787–803. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Mazzaferri EL and Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 97:418–428. 1994. View Article : Google Scholar : PubMed/NCBI | |
|
Santoro M and Vecchio G: Thyroid cancer: A molecular perspective. Mol Cell Endocrinol. 321:1–2. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Robinson MJ and Cobb MH: Mitogen-activated protein kinase pathways. Curr Opin Cell Biol. 9:180–186. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Kohno M and Pouyssegur J: Targeting the ERK signaling pathway in cancer therapy. Ann Med. 38:200–211. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Xing M: BRAF mutation in thyroid cancer. Endocr Relat Cancer. 12:245–262. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Pizzolanti G, Russo L, Richiusa P, Bronte V, Nuara RB, Rodolico V, Amato MC, Smeraldi L, Sisto PS, Nucera M, et al: Fine-needle aspiration molecular analysis for the diagnosis of papillary thyroid carcinoma through BRAF V600E mutation and RET/PTC rearrangement. Thyroid. 17:1109–1115. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Chiosea S, Nikiforova M, Zuo H, Ogilvie J, Gandhi M, Seethala RR, Ohori NP and Nikiforov Y: A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol. 20:122–126. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Santarpia L, Sherman SI, Marabotti A, Clayman GL and El-Naggar AK: Detection and molecular characterization of a novel BRAF activated domain mutation in follicular variant of papillary thyroid carcinoma. Hum Pathol. 40:827–833. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Namba H, Nakashima M, Hayashi T, Hayashida N, Maeda S, Rogounovitch TI, Ohtsuru A, Saenko VA, Kanematsu T and Yamashita S: Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers. J Clin Endocrinol Metab. 88:4393–4397. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, et al: Mutations of the BRAF gene in human cancer. Nature. 417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Nikiforova MN and Nikiforov YE: Molecular genetics of thyroid cancer: Implications for diagnosis, treatment and prognosis. Expert Rev Mol Diagn. 8:83–95. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Project CG, Jones CM, Marshall CJ, Springer CJ, et al: Cancer Genome Project: Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 116:855–867. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Vasko V, Espinosa AV, Scouten W, He H, Auer H, Liyanarachchi S, Larin A, Savchenko V, Francis GL, de la Chapelle A, et al: Gene expression and functional evidence of epithelial-to-mesenchymal transition in papillary thyroid carcinoma invasion. Proc Natl Acad Sci USA. 104:2803–2808. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Nucera C, Lawler J and Parangi S: BRAF(V600E) and microenvironment in thyroid cancer: A functional link to drive cancer progression. Cancer Res. 71:2417–2422. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Schweppe RE, Kerege AA, Sharma V, Poczobutt JM, Gutierrez-Hartmann A, Grzywa RL and Haugen BR: Distinct genetic alterations in the mitogen-activated protein kinase pathway dictate sensitivity of thyroid cancer cells to mitogen-activated protein kinase kinase 1/2 inhibition. Thyroid. 19:825–835. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Xing M: BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications. Endocr Rev. 28:742–762. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Tang KT and Lee CH: BRAF mutation in papillary thyroid carcinoma: Pathogenic role and clinical implications. J Chin Med Assoc. 73:113–128. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, et al: BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab. 90:6373–6379. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Lupi C, Giannini R, Ugolini C, Proietti A, Berti P, Minuto M, Materazzi G, Elisei R, Santoro M, Miccoli P and Basolo F: Association of BRAF V600E mutation with poor clinicopathological outcomes in 500 consecutive cases of papillary thyroid carcinoma. J Clin Endocrinol Metab. 92:4085–4090. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Kim SJ, Lee KE, Myong JP, Park JH, Jeon YK, Min HS, Park SY, Jung KC, Koo Do H and Youn YK: BRAF V600E mutation is associated with tumor aggressiveness in papillary thyroid cancer. World J Surg. 36:310–317. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Frasca F, Nucera C, Pellegriti G, Gangemi P, Attard M, Stella M, Loda M, Vella V, Giordano C, Trimarchi F, et al: BRAF(V600E) mutation and the biology of papillary thyroid cancer. Endocr Relat Cancer. 15:191–205. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Lee KC, Li C, Schneider EB, Wang Y, Somervell H, Krafft M, Umbricht CB and Zeiger MA: Is BRAF mutation associated with lymph node metastasis in patients with papillary thyroid cancer? Surgery. 152:977–983. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kim TY, Kim WB, Song JY, Rhee YS, Gong G, Cho YM, Kim SY, Kim SC, Hong SJ and Shong YK: The BRAF mutation is not associated with poor prognostic factors in Korean patients with conventional papillary thyroid microcarcinoma. Clin Endocrinol (Oxf). 63:588–593. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Liu RT, Chen YJ, Chou FF, Li CL, Wu WL, Tsai PC, Huang CC and Cheng JT: No correlation between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinomas in Taiwan. Clin Endocrinol (Oxf). 63:461–466. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Pelttari H, Schalin-Jäntti C, Arola J, Löyttyniemi E, Knuutila S and Välimäki MJ: BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. APMIS. 120:380–386. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Li X, Abdel-Mageed AB and Kandil E: BRAF mutation in papillary thyroid carcinoma. Int J Clin Exp Med. 5:310–315. 2012.PubMed/NCBI | |
|
Derdas SP, Soulitzis N, Balis V, Sakorafas GH and Spandidos DA: Expression analysis of B-Raf oncogene in V600E-negative benign and malignant tumors of the thyroid gland: Correlation with late disease onset. Med Oncol. 30:3362013. View Article : Google Scholar : PubMed/NCBI | |
|
Li F, Chen G, Sheng C, Aaron GM, Huang Y, Lv Z, Xu H, Xing M and Qu S: BRAFV600E mutation in papillary thyroid microcarcinoma: A meta-analysis. Endocr Relat Cancer. 22:159–168. 2015. View Article : Google Scholar : PubMed/NCBI | |
|
Durante C, Puxeddu E, Ferretti E, Morisi R, Moretti S, Bruno R, Barbi F, Avenia N, Scipioni A, Verrienti A, et al: BRAF mutations in papillary thyroid carcinomas inhibit genes involved in iodine metabolism. J Clin Endocrinol Metab. 92:2840–2843. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Stephen JK, Chitale D, Narra V, Chen KM, Sawhney R and Worsham MJ: DNA methylation in thyroid tumorigenesis. Cancers (Basel). 3:1732–1743. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shimamura M, Nakahara M, Orim F, Kurashige T, Mitsutake N, Nakashima M, Kondo S, Yamada M, Taguchi R, Kimura S, Nagayama Y, et al: Postnatal Expression of BRAFV600E does not induce thyroid cancer in mouse models of thyroid papillary carcinoma. Endocrinology. 154:4423–4430. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Watanabe R, Hayashi Y, Sassa M, Kikumori T, Imai T, Kiuchi T and Murata Y: Possible involvement of BRAFV600E in altered gene expression in papillary thyroid cancer. Endocr J. 56:407–414. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Melillo RM, Castellone MD, Guarino V, De Falco V, Cirafici AM, Salvatore G, Caiazzo F, Basolo F, Giannini R, Kruhoffer M, et al: The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells. J Clin Invest. 115:1068–1081. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Mesa C Jr, Mirza M, Mitsutake N, Sartor M, Medvedovic M, Tomlinson C, Knauf JA, Weber GF and Fagin JA: Conditional activation of RET/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling. Cancer Res. 66:6521–6529. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Palona I, Namba H, Mitsutake N, Starenki D, Podtcheko A, Sedliarou I, Ohtsuru A, Saenko V, Nagayama Y, Umezawa K and Yamashita S: BRAFV600E promotes invasiveness of thyroid cancer cells through nuclear factor kappaB activation. Endocrinology. 147:5699–5707. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Nakayama H, Yoshida A, Nakamura Y, Hayashi H, Miyagi Y, Wada N, Rino Y, Masuda M and Imada T: Clinical significance of BRAF (V600E) mutation and Ki-67 labeling index in papillary thyroid carcinomas. Anticancer Res. 27:3645–3649. 2007.PubMed/NCBI | |
|
Franzoni A, Dima M, D'Agostino M, Puppin C, Fabbro D, Di Loreto C, Pandolfi M, Puxeddu E, Moretti S, Celano M, et al: Prohibitin is overexpressed in papillary thyroid carcinomas bearing the BRAF(V600E) mutation. Thyroid. 19:247–255. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Jo YS, Li S, Song JH, Kwon KH, Lee JC, Rha SY, Lee HJ, Sul JY, Kweon GR, Ro H, et al: Influence of the BRAF V600E mutation on expression of vascular endothelial growth factor in papillary thyroid cancer. J Clin Endocrinol Metab. 91:3667–3670. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Giordano TJ, Kuick R, Thomas DG, Misek DE, Vinco M, Sanders D, Zhu Z, Ciampi R, Roh M, Shedden K, et al: Molecular classification of papillary thyroid carcinoma: Distinct BRAF, RAS, and RET/PTC mutation-specific gene expression profiles discovered by DNA microarray analysis. Oncogene. 24:6646–6656. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Hu S, Liu D, Tufano RP, Carson KA, Rosenbaum E, Cohen Y, Holt EH, Kiseljak-Vassiliades K, Rhoden KJ, Tolaney S, et al: Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer. 119:2322–2329. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Porra V, Ferraro-Peyret C, Durand C, Selmi-Ruby S, Giroud H, Berger-Dutrieux N, Decaussin M, Peix J-L, Bournaud C, Orgiazzi J, et al: Silencing of the tumor suppressor gene SLC5A8 is associated with BRAF mutations in classical papillary thyroid carcinomas. J Clin Endocrinol Metab. 90:3028–3035. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Zane M, Agostini M, Enzo MV, Casal Ide E, Del Bianco P, Torresan F, Merante Boschin I, Pennelli G, Saccani A, Rubello D, et al: Circulating cell-free DNA, SLC5A8 and SLC26A4 hypermethylation, BRAF(V600E): A non-invasive tool panel for early detection of thyroid cancer. Biomed Pharmacother. 67:723–730. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Liu D, Hu S, Hou P, Jiang D, Condouris S and Xing M: Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res. 13:1341–1349. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Puxeddu E, Durante C, Avenia N, Filetti S and Russo D: Clinical implications of BRAF mutation in thyroid carcinoma. Trends Endocrinol Metab. 19:138–145. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Oler G and Cerutti JM: High prevalence of BRAF mutation in a Brazilian cohort of patients with sporadic papillary thyroid carcinomas: Correlation with more aggressive phenotype and decreased expression of iodide-metabolizing genes. Cancer. 115:972–980. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Mian C, Barollo S, Pennelli G, Pavan N, Rugge M, Pelizzo MR, Mazzarotto R, Casara D, Nacamulli D, Mantero F, et al: Molecular characteristics in papillary thyroid cancers (PTCs) with no 131I uptake. Clin Endocrinol (Oxf). 68:108–116. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Romei C, Ciampi R, Faviana P, Agate L, Molinaro E, Bottici V, Basolo F, Miccoli P, Pacini F, Pinchera A and Elisei R: BRAFV600E mutation, but not RET/PTC rearrangements, is correlated with a lower expression of both thyroperoxidase and sodium iodide symporter genes in papillary thyroid cancer. Endocr Relat Cancer. 15:511–520. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Gómez Sáez JM: Diagnostic and prognostic markers in differentiated thyroid cancer. Curr Genomics. 12:597–608. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Baloch ZW, LiVolsi VA, Asa SL, Rosai J, Merino MJ, Randolph G, Vielh P, DeMay RM, Sidawy MK and Frable WJ: Diagnostic terminology and morphologic criteria for cytologic diagnosis of thyroid lesions: A synopsis of the National Cancer Institute Thyroid Fine-Needle Aspiration State of the Science Conference. Diagn Cytopathol. 36:425–437. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, Locker GY, Macdonald JS, Mennel RG, Norton L, et al: Tumor marker utility grading system: A framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst. 88:1456–1466. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Kulasingam V and Diamandis EP: Strategies for discovering novel cancer biomarkers through utilization of emerging technologies. Nat Clin Pract Oncol. 5:588–599. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Xing M: Gene methylation in thyroid tumorigenesis. Endocrinology. 148:948–953. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Dalle Carbonare L, Frigo A, Francia G, Davì MV, Donatelli L, Stranieri C, Brazzarola P, Zatelli MC, Menestrina F and Valenti MT: Runx2 mRNA expression in the tissue, serum, and circulating non-hematopoietic cells of patients with thyroid cancer. J Clin Endocrinol Metab. 97:E1249–E1256. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Yu S, Liu Y, Wang J, Guo Z, Zhang Q, Yu F, Zhang Y, Huang K, Li Y, Song E, et al: Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 97:2084–2092. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Milas M, Shin J, Gupta M, Novosel T, Nasr C, Brainard J, Mitchell J, Berber E and Siperstein A: Circulating thyrotropin receptor mRNA as a novel marker of thyroid cancer: Clinical applications learned from 1758 samples. Ann Surg. 252:643–651. 2010.PubMed/NCBI | |
|
Haugen BR, Woodmansee WW and McDermott MT: Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumors. Clin Endocrinol (Oxf). 56:281–290. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Sahin M, Gursoy A, Tutuncu NB and Guvener DN: Prevalence and prediction of malignancy in cytologically indeterminate thyroid nodules. Clin Endocrinol (Oxf). 65:514–518. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Letsas KP, Andrikoula M and Tsatsoulis A: Fine needle aspiration biopsy-RT-PCR molecular analysis of thyroid nodules: A useful preoperative diagnostic tool. Minerva Endocrinol. 31:179–182. 2006.PubMed/NCBI | |
|
Santoro M, Dathan NA, Berlingieri MT, Bongarzone I, Paulin C, Grieco M, Pierotti MA, Vecchio G and Fusco A: Molecular characterization of RET/PTC3; a novel rearranged version of the RETproto-oncogene in a human thyroid papillary carcinoma. Oncogene. 9:509–516. 1994.PubMed/NCBI | |
|
Pupilli C, Pinzani P, Salvianti F, Fibbi B, Rossi M, Petrone L, Perigli G, De Feo ML, Vezzosi V, Pazzagli M, et al: Circulating BRAFV600E in the diagnosis and follow-up of differentiated papillary thyroid carcinoma. J Clin Endocrinol Metab. 98:3359–3365. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Kebebew E, Weng J, Bauer J, Ranvier G, Clark OH, Duh QY, Shibru D, Bastian B and Griffin A: The prevalence and prognostic value of BRAF mutation in thyroid cancer. Ann Surg. 246:466–471. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Zagzag J, Pollack A, Dultz L, Dhar S, Ogilvie JB, Heller KS, Deng FM and Patel KN: Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma. Surgery. 154:1199–1205. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Espinosa AV, Porchia L and Ringel MD: Targeting BRAF in thyroid cancer. Br J Cancer. 96:16–20. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Cohen Y, Xing M, Mambo E, Guo Z, Wu G, Trink B, Beller U, Westra WH, Ladenson PW and Sidransky D: BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst. 95:625–627. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Henderson YC, Shellenberger TD, Williams MD, El-Naggar AK, Fredrick MJ, Cieply KM and Clayman GL: High rate of BRAF and RET/PTC dual mutations associated with recurrent papillary thyroid carcinoma. Clin Cancer Res. 15:485–491. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Ricarte-Filho JC, Ryder M, Chitale DA, Rivera M, Heguy A, Ladanyi M, Janakiraman M, Solit D, Knauf JA, Tuttle RM, et al: Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1. Cancer Res. 69:4885–4893. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Hoeflich KP, Herter S, Tien J, Wong L, Berry L, Chan J, O'Brien C, Modrusan Z, Seshagiri S, Lackner M, et al: Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression. Cancer Res. 69:3042–3051. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Saji M and Ringel MD: The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors. Mol Cell Endocrinol. 321:20–28. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Montagut C and Settleman J: Targeting the RAF-MEK-ERK pathway in cancer therapy. Cancer Lett. 283:125–34. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Gupta-Abramson V, Troxel AB, Nellore A, Puttaswamy K, Redlinger M, Ransone K, Mandel SJ, Flaherty KT, Loevner LA, O'Dwyer PJ and Brose MS: Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol. 26:4714–4719. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Smalley KS: PLX-4032, a small-molecule B-Raf inhibitor for the potential treatment of malignant melanoma. Curr Opin Investig Drugs. 11:699–706. 2010.PubMed/NCBI | |
|
Salerno P, De Falco V, Tamburrino A, Nappi TC, Vecchio G, Schweppe RE, Bollag G, Santoro M and Salvatore G: Cytostatic activity of adenosine triphosphate-competitive kinase inhibitors in BRAF mutant thyroid carcinoma cells. J Clin Endocrinol Metab. 95:450–455. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Xing J, Liu R, Xing M and Trink B: The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun. 404:958–962. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gillette S, Kong J, Haass NK, et al: Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA. 105:3041–3046. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et al: BRIM-3 Study Group: Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Hauschild A, Grob JJ, Demidov LV, Jouary T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr, Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma: A multicentre, open-label, phase 3 randomised controlled trial. Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Ball DW, Jin N, Rosen DM, Dackiw A, Sidransky D, Xing M and Nelkin BD: Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab. 92:4712–4718. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Liu D, Liu Z, Jiang D, Dackiw AP and Xing M: Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab. 92:4686–4695. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Leboeuf R, Baumgartner JE, Benezra M, Malaguarnera R, Solit D, Pratilas CA, Rosen N, Knauf JA and Fagin JA: BRAFV600E mutation is associated with preferential sensitivity to mitogen-activated protein kinase kinase inhibition in thyroid cancer cell lines. J Clin Endocrinol Metab. 93:2194–2201. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Liu D and Xing M: Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid. 18:853–864. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Xing M: Genetic-targeted therapy of thyroid cancer: A real promise. Thyroid. 19:805–809. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Kimura ET, Nikiforova MN, Zhu Z, Knauf JA, Nikiforov YE and Fagin JA: High prevalence of BRAF mutations in thyroid cancer: Genetic evidence for constitutive activation of the RET/PTC-RAS BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 63:1454–1457. 2003.PubMed/NCBI | |
|
Musholt TJ, Schönefeld S, Schwarz CH, Watzka FM, Musholt PB, Fottner C, Weber MM, Springer E and Schad A: Impact of pathognomonic genetic alterations on the prognosis of papillary thyroid carcinoma. ESES vienna presentation. Langenbecks Arch Surg. 395:877–883. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Sullivan RJ and Flaherty KT: Resistance to BRAF-targeted therapy in melanoma. Eur J Cancer. 49:1297–1304. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Guerra A, Sapio MR, Marotta V, Campanile E, Rossi S, Forno I, Fugazzola L, Budillon A, Moccia T, Fenzi G and Vitale M: The primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinoma. J Clin Endocrinol Metab. 97:517–524. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, Mongare MM, Gould J, Frederick DT, et al: Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature. 487:500–504. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Corcoran RB, Ebi H, Turke AB, Coffee EM, Nishino M, Cogdill AP, Brown RD, Della Pelle P, Dias-Santagata D, Hung KE, et al: EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib. Cancer Discov. 2:227–235. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Prahallad A, Sun C, Huang S, Di Nicolantonio F, Salazar R, Zecchin D, Beijersbergen RL, Bardelli A and Bernards R: Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR. Nature. 483:100–103. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, et al: Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 367:1694–703. 2012. View Article : Google Scholar : PubMed/NCBI |
